Skip to main content
TipRanks
Go Ultimate75% OFF

Dianthus Therapeutics (87E) Drug Pipeline

0 Followers
Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
Claseprubart, Dnth103Myasthenia Gravis, GeneralizedPhase IIIRecruitingA Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)May 27, 2026―
Dnth103Chronic Inflammatory Demyelinating PolyneuropathyPhase IIIRecruitingA Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)Feb 18, 2025
Dnth103Multifocal Motor NeuropathyPhase IIRecruitingA Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor NeuropathyJul 31, 2024
Dnth103Myasthenia Gravis, GeneralizedPhase IIActive Not RecruitingA Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)Dec 15, 2023―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Dianthus Therapeutics, Inc. (DE:87E) have in its pipeline
Dianthus Therapeutics DE:87E is currently developing the following drugs: Claseprubart, Dnth103, Dnth103. These drug candidates are in various stages of clinical development as the company works toward FDA approval.